SavedAdd your journal

Journals / Abant Tıp Dergisi / 2013 / Cilt: 2 - Sayı: 3

Carvedilol and Metoprolol in Acute Myocardial Infarction Early Effect of Oxidized LDL and Paraoxonase-1 Activity

Akut Miyokard İnfarktüsünde Karvedilol ve Metoprolol’ün Okside LDL ve Paraoksonaz-1 Aktivitesine Erken Dönem Etkisi

Sezgin ALBAYRAK
Kemal KARAAĞAÇ
İbrahim BARAN
Zeynel Abidin YETGİN
Hakan UÇAR
Ali AYDINLAR
Pages
179–184
Publication Date
2013-09-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

But one month period may not be enough to determine this effect.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: The aim of this study to investigate the effects of Carvedilol and Metoprolol on oxidized low density lipoprotein oxLDL and paraoxonase-1 PON-1 activity in patients with acute myocardial infarction who were treated with these agents for four weeks.
📊
Key Findings & Data:Method: 31 patients with AMI and 15 healhty subjects for control group were contained. 15 patients of AMI group were given Carvedilol treatment and the remained 16 were given Metoprolol treatment and the study was randomized to two groups.
💡
Conclusion & Impact:But one month period may not be enough to determine this effect.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Koroner arter hastalığı · okside LDL · paraoksanaz-1

Abstract

Objective: The aim of this study to investigate the effects of Carvedilol and Metoprolol on oxidized low density lipoprotein oxLDL and paraoxonase-1 PON-1 activity in patients with acute myocardial infarction who were treated with these agents for four weeks. Method: 31 patients with AMI and 15 healhty subjects for control group were contained. 15 patients of AMI group were given Carvedilol treatment and the remained 16 were given Metoprolol treatment and the study was randomized to two groups. At the end of the study oxLDL and PON-1 activity levels were studied from the blood samples taken at admission pre treatment and samples taken after one month treatment. Results: In patient group initial high density lipoprotein HDL level and PON-1 activity were found significantly lower but oxLDL level was higher in patient group compared to control group. The oxLDL levels were found to decrease in patient group after Carvedilol p=0,008 and Metoprolol p Conclusion: In paralel to other studies we showed that oxLDL is increased and HDL and PON-1 activity is decreased in patients with AMI. Carvedilol may be expected to be superior to Metoprolol due to its antioxidant effect in increasing PON-1 acitvity. But one month period may not be enough to determine this effect.

Özet

Amaç: Bu çalışmanın amacı akut miyokard infarktüsü AMİ geçiren hastalarda dört haftalık karvedilol ve metoprolol tedavisinin okside düşük yoğunluklu lipoprotein LDL düzeyi ve paraoksanaz-1 PON-1 aktivitesi üzerine etkisini araştırmaktır. Yöntem: Çalışmaya AMİ tanısı konulan 31 hasta ve kontrol grubunu oluşturacak 15 olgu alındı. AMİ grubundan 15 hastaya karvedilol ve 16 hastaya metoprolol tedavisi verilerek çalışma iki guruba randomize edildi. Çalışmanın sonunda başvuru ve kontrol vizitinde alınan ve saklanan kan örneklerinden okside LDL’nin ve PON-1 aktivitesinin başvuru tedavi öncesi ve tedavi sonrası 1 aylık sonuçlarına bakıldı. Bulgular: Hasta grubunda kontrol grubuna kıyasla başlangıç HDL düzeyi ve PON-1 aktivitesi anlamlı derecede düşük olarak saptandı. Okside LDL düzeyi hasta grubunda kontrol grubuna göre daha yüksekti. Hasta grubunda 1 aylık karvedilol p=0,008 ve metoprolol p Sonuç: AMİ geçiren hastalarda diğer çalışmalara paralel olarak, okside LDL' nin arttığı ve HDL-K düzeyi ile PON-1 aktivitesinin azaldığı gösterildi. Antioksidan özellikleri nedeniyle Karvedilol’ün PON-1 aktivitesini arttırmada Metoprolol’e göre daha üstün olması beklenebilir. Fakat bir aylık süre bunu göstermek için yeterli olmayabilir.

🔖

Cite This Article

ALBAYRAK, S., KARAAĞAÇ, K., BARAN, İ., YETGİN, Z. A., UÇAR, H., AYDINLAR, A. (2013). Carvedilol and Metoprolol in Acute Myocardial Infarction Early Effect of Oxidized LDL and Paraoxonase-1 Activity. Abant Tıp Dergisi, Cilt: 2 - Sayı: 3, 179–184. https://ajindex.com/articles/449106

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Ross R. The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993
  2. 362(6423):801-9 2.Carmena R, Ascaso JF, Camejo G, Varela G, Hurt-Camejo E, Ordovas JM, et al. Effect of olive and sunflower oils on low density lipoprotein level, composition, size, oxidation and interaction with arterial proteoglycans. Atherosclerosis. 1996
  3. 125(2):243-55. 3.Tsimikas S, Brilakis ES, Miller ER, McConnell JP, Lennon RJ, Kornman KS, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005
  4. 353(1):46-57 4.Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett 1991
  5. 286(1-2): 152–4. 5.Mackness MI, Mackness B, Durrington PN, Connelly PW, HegeleRA. Paraoxonase: biochemistry, genetics and relationship to plasmalipoproteins. Curr Opin Lipidol 1996
  6. 7(2): 69–76. 6.Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, et al. Human serum paraoxonase is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Free Radic Biol Med 1999
  7. 26(7-8): 892–904. 7.Eckerson HW, Wyte CM, La Du BN. The human serum paraoxonase/ arylesterase polymorphism. Am J Hum Genet 1983
  8. 35(6): 1126-38. 8.Yusuf S, Sleight P, Rosi PRF, Ramsdale D, Peto R, Furze L, et al. Reduction in infarct size, arrhythmias, chest pain, and morbidity by early intravenous beta-blockade in suspected acute myocardial infarction. Circulation 1983
  9. 67 (6 Pt 2): I32-41. 9.Feuerstein GZ, Hamburger SA, Smith EF, Bril A, Ruffolo RR, Myocardial protection with Carvedilol. J Cardiovasc Pharmacol 1992
  10. S138-41. 10.McElveen J, Mackness MI, Colley CM, Peard T, Warner S, Walker CH. Distribution of paraoxon hydrolytic activity in the serum of patients after myocardial infarction. Clin Chem1986
  11. 32(4): 671-3. 11.Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, et al. The Gln-Argl92 polymorphism of human paraoxonase gene ıs not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 1998
  12. 18(10):1611-6. 12.Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions. Circulation 2000
  13. 101(21): 2510-7. 13.Aviram M, Rosenblat M, Bisgair CL, Newton RS, PrimoParmo SL, La Du BN Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions: a possible peroxidative r